Hodgkin's disease. Results from a program in radiation therapy

Area of Science:

• Oncology
• Radiation Oncology
• Clinical Medicine

Background:

• Hodgkin's disease staging and treatment have evolved significantly.
• Understanding the impact of radiation therapy on prognosis is crucial for patient outcomes.

Purpose of the Study:

• To retrospectively analyze the outcomes of patients with Stage I-A, II-A, and III-A Hodgkin's disease treated with radiation therapy.
• To determine the impact of cell type, clinical and pathologic stage, and tumor bulk on patient prognosis.

Main Methods:

• Retrospective analysis of 122 Hodgkin's disease patients treated between January 1965 and December 1975.
• Categorization of patients by clinical and pathologic stage (I-A, II-A, III-A).
• Evaluation of different radiation therapy techniques including involved-field, limited-field, and extended-field radiation therapy.

Main Results:

• Extended-field radiation therapy for Stage I-A Hodgkin's disease showed 100% relapse-free survival at 5 and 9 years.
• For Stage II-A, extended-field radiation therapy resulted in 88% overall survival and 82% relapse-free survival at 5 years.
• Pathologically staged II-A patients treated with various techniques had 95% overall survival and 75% relapse-free survival at 5 and 10 years.
• Stage III-A patients had a 79% overall survival and 58% relapse-free survival at 5 years.

Conclusions:

• Extended-field radiation therapy is associated with superior survival outcomes in early-stage Hodgkin's disease.
• Pathologic staging and appropriate radiation therapy techniques are critical for optimizing patient prognosis.
• While effective, radiation therapy can lead to complications such as hypothyroidism and neuropathy.